{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-25-000047","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.590679+00:00","generated_at":"2026-05-17T18:43:45.136400+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ligand Q2 royalties up 57% to $36.4M; raises FY2025 guidance to $200-225M revenue and $6.70-7.00 adj. EPS","bullets":["Q2 revenue $47.6M (+15% YoY); royalties $36.4M (+57%) driven by Qarziba and Filspari.","GAAP net income $4.8M ($0.24 diluted) vs loss $51.9M in Q2 2024; core adj. EPS $1.60 vs $1.40.","FY2025 guidance raised: revenue $200-225M (prev $180-200M), adj. EPS $6.70-7.00 (prev $6.00-6.25).","Pelthos merger closed; Zelsuvmi launched July 10; Ligand earned $5M milestone and 13% royalty.","Merck acquiring Verona for ~$10B; Ligand holds 3% royalty on Ohtuvayre (COPD)."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-25-000047","json":"https://secwatch.observer/filing/0000886163-25-000047.json","markdown":"https://secwatch.observer/filing/0000886163-25-000047.md","text":"https://secwatch.observer/filing/0000886163-25-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000047/0000886163-25-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000047/lgnd-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:43:45.136400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}